Tapewire

Nasdaq · USD

INSM

INSMED Inc

Export transactions ↓
Tapewire entity
3174
SEC CIK
0001104506
Parsed reports
490

Last 12 months

Inside the activity.

0 purchase rows · 169 sale rows

Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.
Monthly counts
MonthPurchasesSales
Nov 2025023
Dec 2025018
Jan 2026044
Feb 2026022
Mar 202608
Apr 2026010
May 2026019
Jun 2026013
Jul 202607
Aug 202604
Sep 202601
Oct 202600

Latest available

Insider transactions

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateOwner / reported roleActivity / securityShares / unitsReported priceReported valueDetails
February 09, 2026 Filed Feb 11, 2026 21:43 UTC GiftCommon Stock 53,400 $0.00 $0.00
Disclosure

SEC source: 0001219023-26-000002 · wk-form4_1770846185.xml · nonDerivative · entry 1

MCGIRR DAVID W J · CIK 0001219023 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 44,323

Read SEC document
February 09, 2026 Filed Feb 11, 2026 21:42 UTC
Lewis WilliamDirector · Chair and CEO
Exercise / conversionStock Option (right to buy) · Derivative 6,259 $0.00 Strike: $30.46 $0.00
Disclosure

SEC source: 0001402051-26-000013 · wk-form4_1770846139.xml · derivative · entry 9

Lewis William · CIK 0001402051 · Director · Chair and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 68,850

Underlying: Common Stock · 6,259 shares

Expires 2028-01-04

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

F5 · derivative.exercise_date: The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant.

Read SEC document
February 09, 2026 Filed Feb 11, 2026 21:42 UTC
Lewis WilliamDirector · Chair and CEO
Exercise / conversionStock Option (right to buy) · Derivative 4,440 $0.00 Strike: $17.16 $0.00
Disclosure

SEC source: 0001402051-26-000013 · wk-form4_1770846139.xml · derivative · entry 8

Lewis William · CIK 0001402051 · Director · Chair and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 48,840

Underlying: Common Stock · 4,440 shares

Expires 2027-05-17

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

F5 · derivative.exercise_date: The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant.

Read SEC document
February 09, 2026 Filed Feb 11, 2026 21:42 UTC
Lewis WilliamDirector · Chair and CEO
SaleCommon Stock 1,287 $148.83 $191,544.21
Disclosure

SEC source: 0001402051-26-000013 · wk-form4_1770846139.xml · nonDerivative · entry 5

Lewis William · CIK 0001402051 · Director · Chair and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 301,185

F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

F4 · price: This is the weighted average sales price representing 1,287 shares sold at prices ranging from $148.62 to $149.35 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.

Read SEC document
February 09, 2026 Filed Feb 11, 2026 21:42 UTC
Lewis WilliamDirector · Chair and CEO
SaleCommon Stock 7,221 $148.02 $1,068,852.42
Disclosure

SEC source: 0001402051-26-000013 · wk-form4_1770846139.xml · nonDerivative · entry 4

Lewis William · CIK 0001402051 · Director · Chair and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 302,472

F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

F3 · price: This is the weighted average sales price representing 7,221 shares sold at prices ranging from $147.61 to $148.60 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.

Read SEC document
February 09, 2026 Filed Feb 11, 2026 21:42 UTC
Lewis WilliamDirector · Chair and CEO
SaleCommon Stock 4,888 $147.17 $719,366.96
Disclosure

SEC source: 0001402051-26-000013 · wk-form4_1770846139.xml · nonDerivative · entry 3

Lewis William · CIK 0001402051 · Director · Chair and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 309,693

F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

F2 · price: This is the weighted average sales price representing 4,888 shares sold at prices ranging from $146.61 to $147.60 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.

Read SEC document
February 09, 2026 Filed Feb 11, 2026 21:42 UTC
Lewis WilliamDirector · Chair and CEO
Exercise / conversionCommon Stock 6,259 $30.46 $190,649.14
Disclosure

SEC source: 0001402051-26-000013 · wk-form4_1770846139.xml · nonDerivative · entry 2

Lewis William · CIK 0001402051 · Director · Chair and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 314,581

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

Read SEC document
February 09, 2026 Filed Feb 11, 2026 21:42 UTC
Lewis WilliamDirector · Chair and CEO
Exercise / conversionCommon Stock 4,440 $17.16 $76,190.40
Disclosure

SEC source: 0001402051-26-000013 · wk-form4_1770846139.xml · nonDerivative · entry 1

Lewis William · CIK 0001402051 · Director · Chair and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 308,322

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

Read SEC document
February 05, 2026 Filed Feb 6, 2026 21:18 UTC
Flammer Martina M.D.Chief Medical Officer
SaleCommon Stock 869 $152.44 $132,470.36
Disclosure

SEC source: 0001796960-26-000010 · wk-form4_1770412728.xml · nonDerivative · entry 1

Flammer Martina M.D. · CIK 0001796960 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 83,243

F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on February 27, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

Read SEC document
February 03, 2026 Filed Feb 4, 2026 21:20 UTC
Adsett RogerChief Operating Officer
SaleCommon Stock 791 $156.17 $123,530.47
Disclosure

SEC source: 0001685904-26-000006 · wk-form4_1770240004.xml · nonDerivative · entry 1

Adsett Roger · CIK 0001685904 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 106,810

F1 · kind: Shares sold to satisfy tax withholding obligations upon the vesting of Restricted Stock Units and to cover related broker fees.

Read SEC document
February 03, 2026 Filed Feb 4, 2026 21:19 UTC
Bonstein SaraChief Financial Officer
SaleCommon Stock 748 $156.34 $116,942.32
Disclosure

SEC source: 0001604019-26-000006 · wk-form4_1770239979.xml · nonDerivative · entry 1

Bonstein Sara · CIK 0001604019 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 79,758

F1 · kind: Shares sold to satisfy tax withholding obligations upon the vesting of Restricted Stock Units and to cover related broker fees.

Read SEC document
February 03, 2026 Filed Feb 4, 2026 21:17 UTC
Lewis WilliamDirector · Chair and CEO
SaleCommon Stock 3,009 $156.34 $470,427.06
Disclosure

SEC source: 0001402051-26-000011 · wk-form4_1770239840.xml · nonDerivative · entry 1

Lewis William · CIK 0001402051 · Director · Chair and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 303,882

F1 · kind: Shares sold to satisfy tax withholding obligations upon the vesting of Restricted Stock Units and to cover related broker fees.

Read SEC document
February 03, 2026 Filed Feb 4, 2026 21:15 UTC
Smith Michael AlexanderChief Legal Officer
SaleCommon Stock 640 $156.27 $100,012.80
Disclosure

SEC source: 0001870278-26-000006 · wk-form4_1770239741.xml · nonDerivative · entry 1

Smith Michael Alexander · CIK 0001870278 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 56,397

F1 · kind: Shares sold to satisfy tax withholding obligations upon the vesting of Restricted Stock Units and to cover related broker fees.

Read SEC document
February 03, 2026 Filed Feb 4, 2026 21:15 UTC
Flammer Martina M.D.Chief Medical Officer
SaleCommon Stock 795 $155.77 $123,837.15
Disclosure

SEC source: 0001796960-26-000008 · wk-form4_1770239710.xml · nonDerivative · entry 7

Flammer Martina M.D. · CIK 0001796960 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 84,112

F6 · kind: Shares sold to satisfy tax withholding obligations upon the vesting of Restricted Stock Units and to cover related broker fees.

Read SEC document
February 02, 2026 Filed Feb 4, 2026 21:15 UTC
Flammer Martina M.D.Chief Medical Officer
Exercise / conversionStock Option (right to buy) · Derivative 7,982 $0.00 Strike: $65.72 $0.00
Disclosure

SEC source: 0001796960-26-000008 · wk-form4_1770239710.xml · derivative · entry 8

Flammer Martina M.D. · CIK 0001796960 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 23,948

Underlying: Common Stock · 7,982 shares

Expires 2035-01-08

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on February 27, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

F7 · derivative.exercise_date: These stock options were granted under the Company's Amended and Restated 2019 Incentive Plan, as amended. The options become exercisable based on the following vesting schedule: 25% vest on the first day of the first month following the first anniversary of the date of grant and an additional 12.5% vest every six months thereafter until fully vested.

Read SEC document
February 02, 2026 Filed Feb 4, 2026 21:15 UTC
Flammer Martina M.D.Chief Medical Officer
SaleCommon Stock 100 $156.86 $15,686.00
Disclosure

SEC source: 0001796960-26-000008 · wk-form4_1770239710.xml · nonDerivative · entry 6

Flammer Martina M.D. · CIK 0001796960 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 84,907

F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on February 27, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

Read SEC document
February 02, 2026 Filed Feb 4, 2026 21:15 UTC
Flammer Martina M.D.Chief Medical Officer
SaleCommon Stock 3,042 $155.46 $472,909.32
Disclosure

SEC source: 0001796960-26-000008 · wk-form4_1770239710.xml · nonDerivative · entry 5

Flammer Martina M.D. · CIK 0001796960 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 85,007

F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on February 27, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

F5 · price: This is the weighted average sales price representing 3,042 shares sold at prices ranging from $155.10 to $155.96 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.

Read SEC document
February 02, 2026 Filed Feb 4, 2026 21:15 UTC
Flammer Martina M.D.Chief Medical Officer
SaleCommon Stock 3,349 $154.56 $517,621.44
Disclosure

SEC source: 0001796960-26-000008 · wk-form4_1770239710.xml · nonDerivative · entry 4

Flammer Martina M.D. · CIK 0001796960 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 88,049

F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on February 27, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

F4 · price: This is the weighted average sales price representing 3,349 shares sold at prices ranging from $154.10 to $155.09 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.

Read SEC document
February 02, 2026 Filed Feb 4, 2026 21:15 UTC
Flammer Martina M.D.Chief Medical Officer
SaleCommon Stock 928 $153.16 $142,132.48
Disclosure

SEC source: 0001796960-26-000008 · wk-form4_1770239710.xml · nonDerivative · entry 3

Flammer Martina M.D. · CIK 0001796960 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 91,398

F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on February 27, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

F3 · price: This is the weighted average sales price representing 928 shares sold at prices ranging from $152.77 to $153.31 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.

Read SEC document
February 02, 2026 Filed Feb 4, 2026 21:15 UTC
Flammer Martina M.D.Chief Medical Officer
SaleCommon Stock 563 $152.06 $85,609.78
Disclosure

SEC source: 0001796960-26-000008 · wk-form4_1770239710.xml · nonDerivative · entry 2

Flammer Martina M.D. · CIK 0001796960 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 92,326

F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on February 27, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

F2 · price: This is the weighted average sales price representing 563 shares sold at prices ranging from $151.76 to $152.74 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.

Read SEC document
February 02, 2026 Filed Feb 4, 2026 21:15 UTC
Flammer Martina M.D.Chief Medical Officer
Exercise / conversionCommon Stock 7,982 $65.72 $524,577.04
Disclosure

SEC source: 0001796960-26-000008 · wk-form4_1770239710.xml · nonDerivative · entry 1

Flammer Martina M.D. · CIK 0001796960 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 92,889

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on February 27, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

Read SEC document
January 20, 2026 Filed Jan 22, 2026 21:28 UTC
Lewis WilliamDirector · Chair and CEO
Exercise / conversionStock Option (right to buy) · Derivative 4,440 $0.00 Strike: $17.16 $0.00
Disclosure

SEC source: 0001402051-26-000009 · wk-form4_1769117327.xml · derivative · entry 11

Lewis William · CIK 0001402051 · Director · Chair and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 53,280

Underlying: Common Stock · 4,440 shares

Expires 2027-05-17

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

F7 · derivative.exercise_date: The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant.

Read SEC document
January 20, 2026 Filed Jan 22, 2026 21:28 UTC
Lewis WilliamDirector · Chair and CEO
Exercise / conversionStock Option (right to buy) · Derivative 6,259 $0.00 Strike: $30.46 $0.00
Disclosure

SEC source: 0001402051-26-000009 · wk-form4_1769117327.xml · derivative · entry 10

Lewis William · CIK 0001402051 · Director · Chair and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 75,109

Underlying: Common Stock · 6,259 shares

Expires 2028-01-04

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

F7 · derivative.exercise_date: The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant.

Read SEC document
January 20, 2026 Filed Jan 22, 2026 21:28 UTC
Lewis WilliamDirector · Chair and CEO
SaleCommon Stock 254 $160.70 $40,817.80
Disclosure

SEC source: 0001402051-26-000009 · wk-form4_1769117327.xml · nonDerivative · entry 7

Lewis William · CIK 0001402051 · Director · Chair and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 306,891

F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

F6 · price: This is the weighted average sales price representing 254 shares sold at prices ranging from $160.58 to $160.76 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.

Read SEC document
January 20, 2026 Filed Jan 22, 2026 21:28 UTC
Lewis WilliamDirector · Chair and CEO
SaleCommon Stock 2,229 $159.85 $356,305.65
Disclosure

SEC source: 0001402051-26-000009 · wk-form4_1769117327.xml · nonDerivative · entry 6

Lewis William · CIK 0001402051 · Director · Chair and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 307,145

F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

F5 · price: This is the weighted average sales price representing 2,229 shares sold at prices ranging from $159.55 to $160.32 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.

Read SEC document
January 20, 2026 Filed Jan 22, 2026 21:28 UTC
Lewis WilliamDirector · Chair and CEO
SaleCommon Stock 5,967 $158.99 $948,693.33
Disclosure

SEC source: 0001402051-26-000009 · wk-form4_1769117327.xml · nonDerivative · entry 5

Lewis William · CIK 0001402051 · Director · Chair and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 309,374

F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

F4 · price: This is the weighted average sales price representing 5,967 shares sold at prices ranging from $158.55 to $159.52 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.

Read SEC document
January 20, 2026 Filed Jan 22, 2026 21:28 UTC
Lewis WilliamDirector · Chair and CEO
SaleCommon Stock 1,243 $158.37 $196,853.91
Disclosure

SEC source: 0001402051-26-000009 · wk-form4_1769117327.xml · nonDerivative · entry 4

Lewis William · CIK 0001402051 · Director · Chair and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 315,341

F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

F3 · price: This is the weighted average sales price representing 1,243 shares sold at prices ranging from $157.54 to $158.53 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.

Read SEC document
January 20, 2026 Filed Jan 22, 2026 21:28 UTC
Lewis WilliamDirector · Chair and CEO
SaleCommon Stock 1,006 $156.80 $157,740.80
Disclosure

SEC source: 0001402051-26-000009 · wk-form4_1769117327.xml · nonDerivative · entry 3

Lewis William · CIK 0001402051 · Director · Chair and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 316,584

F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

F2 · price: This is the weighted average sales price representing 1,006 shares sold at prices ranging from $156.53 to $157.50 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.

Read SEC document
January 20, 2026 Filed Jan 22, 2026 21:28 UTC
Lewis WilliamDirector · Chair and CEO
Exercise / conversionCommon Stock 4,440 $17.16 $76,190.40
Disclosure

SEC source: 0001402051-26-000009 · wk-form4_1769117327.xml · nonDerivative · entry 2

Lewis William · CIK 0001402051 · Director · Chair and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 317,590

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

Read SEC document
January 20, 2026 Filed Jan 22, 2026 21:28 UTC
Lewis WilliamDirector · Chair and CEO
Exercise / conversionCommon Stock 6,259 $30.46 $190,649.14
Disclosure

SEC source: 0001402051-26-000009 · wk-form4_1769117327.xml · nonDerivative · entry 1

Lewis William · CIK 0001402051 · Director · Chair and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 313,150

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

Read SEC document
January 12, 2026 Filed Jan 13, 2026 21:04 UTC
Lewis WilliamDirector · Chair and CEO
Exercise / conversionStock Option (right to buy) · Derivative 4,440 $0.00 Strike: $17.16 $0.00
Disclosure

SEC source: 0001402051-26-000007 · wk-form4_1768338242.xml · derivative · entry 13

Lewis William · CIK 0001402051 · Director · Chair and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 57,720

Underlying: Common Stock · 4,440 shares

Expires 2027-05-17

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

F8 · derivative.exercise_date: The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant.

Read SEC document
January 12, 2026 Filed Jan 13, 2026 21:04 UTC
Lewis WilliamDirector · Chair and CEO
Exercise / conversionStock Option (right to buy) · Derivative 6,259 $0.00 Strike: $30.46 $0.00
Disclosure

SEC source: 0001402051-26-000007 · wk-form4_1768338242.xml · derivative · entry 12

Lewis William · CIK 0001402051 · Director · Chair and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 81,368

Underlying: Common Stock · 6,259 shares

Expires 2028-01-04

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

F8 · derivative.exercise_date: The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant.

Read SEC document
January 12, 2026 Filed Jan 13, 2026 21:04 UTC
Lewis WilliamDirector · Chair and CEO
SaleCommon Stock 315 $174.86 $55,080.90
Disclosure

SEC source: 0001402051-26-000007 · wk-form4_1768338242.xml · nonDerivative · entry 9

Lewis William · CIK 0001402051 · Director · Chair and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 306,891

F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

Read SEC document
January 12, 2026 Filed Jan 13, 2026 21:04 UTC
Lewis WilliamDirector · Chair and CEO
SaleCommon Stock 297 $172.36 $51,190.92
Disclosure

SEC source: 0001402051-26-000007 · wk-form4_1768338242.xml · nonDerivative · entry 8

Lewis William · CIK 0001402051 · Director · Chair and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 307,206

F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

F7 · price: This is the weighted average sales price representing 297 shares sold at prices ranging from $172.26 to $172.42 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.

Read SEC document
January 12, 2026 Filed Jan 13, 2026 21:04 UTC
Lewis WilliamDirector · Chair and CEO
SaleCommon Stock 297 $171.31 $50,879.07
Disclosure

SEC source: 0001402051-26-000007 · wk-form4_1768338242.xml · nonDerivative · entry 7

Lewis William · CIK 0001402051 · Director · Chair and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 307,503

F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

F6 · price: This is the weighted average sales price representing 297 shares sold at prices ranging from $171.21 to $171.52 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.

Read SEC document
January 12, 2026 Filed Jan 13, 2026 21:04 UTC
Lewis WilliamDirector · Chair and CEO
SaleCommon Stock 160 $170.24 $27,238.40
Disclosure

SEC source: 0001402051-26-000007 · wk-form4_1768338242.xml · nonDerivative · entry 6

Lewis William · CIK 0001402051 · Director · Chair and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 307,800

F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

F5 · price: This is the weighted average sales price representing 160 shares sold at prices ranging from $170.12 to $170.89 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.

Read SEC document
January 12, 2026 Filed Jan 13, 2026 21:04 UTC
Lewis WilliamDirector · Chair and CEO
SaleCommon Stock 6,996 $169.57 $1,186,311.72
Disclosure

SEC source: 0001402051-26-000007 · wk-form4_1768338242.xml · nonDerivative · entry 5

Lewis William · CIK 0001402051 · Director · Chair and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 307,960

F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

F4 · price: This is the weighted average sales price representing 6,996 shares sold at prices ranging from $169.11 to $170.08 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.

Read SEC document
January 12, 2026 Filed Jan 13, 2026 21:04 UTC
Lewis WilliamDirector · Chair and CEO
SaleCommon Stock 7,176 $168.63 $1,210,088.88
Disclosure

SEC source: 0001402051-26-000007 · wk-form4_1768338242.xml · nonDerivative · entry 4

Lewis William · CIK 0001402051 · Director · Chair and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 314,956

F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

F3 · price: This is the weighted average sales price representing 7,176 shares sold at prices ranging from $168.11 to $169.10 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.

Read SEC document
January 12, 2026 Filed Jan 13, 2026 21:04 UTC
Lewis WilliamDirector · Chair and CEO
SaleCommon Stock 3,974 $167.73 $666,559.02
Disclosure

SEC source: 0001402051-26-000007 · wk-form4_1768338242.xml · nonDerivative · entry 3

Lewis William · CIK 0001402051 · Director · Chair and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 322,132

F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

F2 · price: This is the weighted average sales price representing 3,974 shares sold at prices ranging from $167.11 to $168.02 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.

Read SEC document
January 12, 2026 Filed Jan 13, 2026 21:04 UTC
Lewis WilliamDirector · Chair and CEO
Exercise / conversionCommon Stock 4,440 $17.16 $76,190.40
Disclosure

SEC source: 0001402051-26-000007 · wk-form4_1768338242.xml · nonDerivative · entry 2

Lewis William · CIK 0001402051 · Director · Chair and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 326,106

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

Read SEC document
January 12, 2026 Filed Jan 13, 2026 21:04 UTC
Lewis WilliamDirector · Chair and CEO
Exercise / conversionCommon Stock 6,259 $30.46 $190,649.14
Disclosure

SEC source: 0001402051-26-000007 · wk-form4_1768338242.xml · nonDerivative · entry 1

Lewis William · CIK 0001402051 · Director · Chair and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 321,666

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

Read SEC document
January 09, 2026 Filed Jan 13, 2026 21:03 UTC
Flammer Martina M.D.Chief Medical Officer
SaleCommon Stock 1,887 $186.19 $351,340.53
Disclosure

SEC source: 0001796960-26-000006 · wk-form4_1768338200.xml · nonDerivative · entry 1

Flammer Martina M.D. · CIK 0001796960 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 84,907

F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on February 27, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

Read SEC document
January 08, 2026 Filed Jan 8, 2026 22:22 UTC
Adsett RogerChief Operating Officer
SaleCommon Stock 2,059 $174.17 $358,616.03
Disclosure

SEC source: 0001685904-26-000004 · wk-form4_1767910926.xml · nonDerivative · entry 3

Adsett Roger · CIK 0001685904 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 107,601

F1 · kind: Shares sold to satisfy tax withholding obligations upon the vesting of Restricted Stock Units and to cover related broker fees.

Read SEC document
January 08, 2026 Filed Jan 8, 2026 22:21 UTC
Bonstein SaraChief Financial Officer
SaleCommon Stock 1,447 $174.17 $252,023.99
Disclosure

SEC source: 0001604019-26-000004 · wk-form4_1767910881.xml · nonDerivative · entry 3

Bonstein Sara · CIK 0001604019 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 80,506

F1 · kind: Shares sold to satisfy tax withholding obligations upon the vesting of Restricted Stock Units and to cover related broker fees.

Read SEC document
January 08, 2026 Filed Jan 8, 2026 22:20 UTC
Flammer Martina M.D.Chief Medical Officer
SaleCommon Stock 3,251 $174.17 $566,226.67
Disclosure

SEC source: 0001796960-26-000004 · wk-form4_1767910845.xml · nonDerivative · entry 8

Flammer Martina M.D. · CIK 0001796960 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 86,794

F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on February 27, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

Read SEC document
January 08, 2026 Filed Jan 8, 2026 22:20 UTC
Flammer Martina M.D.Chief Medical Officer
SaleCommon Stock 1,660 $173.87 $288,624.20
Disclosure

SEC source: 0001796960-26-000004 · wk-form4_1767910845.xml · nonDerivative · entry 7

Flammer Martina M.D. · CIK 0001796960 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 90,045

F5 · kind: Shares sold to satisfy tax withholding obligations upon the vesting of Restricted Stock Units and to cover related broker fees.

F7 · price: This is the weighted average sales price representing 1,660 shares sold at prices ranging from $173.87 to $173.90 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.

Read SEC document
January 08, 2026 Filed Jan 8, 2026 22:20 UTC
Lewis WilliamDirector · Chair and CEO
SaleCommon Stock 3,223 $174.17 $561,349.91
Disclosure

SEC source: 0001402051-26-000005 · wk-form4_1767910807.xml · nonDerivative · entry 3

Lewis William · CIK 0001402051 · Director · Chair and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 315,407

F1 · kind: Shares sold to satisfy tax withholding obligations upon the vesting of Restricted Stock Units and to cover related broker fees.

Read SEC document
January 08, 2026 Filed Jan 8, 2026 22:19 UTC
Smith Michael AlexanderChief Legal Officer
SaleCommon Stock 1,053 $174.17 $183,401.01
Disclosure

SEC source: 0001870278-26-000004 · wk-form4_1767910777.xml · nonDerivative · entry 3

Smith Michael Alexander · CIK 0001870278 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 57,037

F1 · kind: Shares sold to satisfy tax withholding obligations upon the vesting of Restricted Stock Units and to cover related broker fees.

Read SEC document
January 07, 2026 Filed Jan 8, 2026 22:22 UTC
Adsett RogerChief Operating Officer
SaleCommon Stock 802 $175.07 $140,406.14
Disclosure

SEC source: 0001685904-26-000004 · wk-form4_1767910926.xml · nonDerivative · entry 2

Adsett Roger · CIK 0001685904 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 109,660

F1 · kind: Shares sold to satisfy tax withholding obligations upon the vesting of Restricted Stock Units and to cover related broker fees.

Read SEC document
January 07, 2026 Filed Jan 8, 2026 22:21 UTC
Bonstein SaraChief Financial Officer
SaleCommon Stock 1,678 $175.07 $293,767.46
Disclosure

SEC source: 0001604019-26-000004 · wk-form4_1767910881.xml · nonDerivative · entry 2

Bonstein Sara · CIK 0001604019 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 81,953

F1 · kind: Shares sold to satisfy tax withholding obligations upon the vesting of Restricted Stock Units and to cover related broker fees.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.